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DJ-1etic ﬁndings have changed our views on Parkinson's disease (PD), as mutations in
a growing number of genes are found to cause monogenic forms of the disorder. Point mutations in the gene
for α-synuclein, as well as duplications and triplications of the wild-type gene cause a dominant form of PD
in rare families, pointing towards mishandling of this protein as a crucial step in the molecular pathogenesis
of the disorder. Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) have recently been identiﬁed
as a much more common cause for dominant PD, while mutations in the parkin gene, in DJ-1, PINK1 and
ATP13A2 all cause autosomal-recessive parkinsonism of early onset. Mutations in recessive genes probably
are pathogenic through loss-of-function mechanisms, suggesting that their wild-type products protect
dopaminergic cells against a variety of insults. Evidence is emerging that at least some of these genes may
play a direct role in the etiology of the common sporadic form of PD. Further, it is likely that the cellular
pathways identiﬁed in rare monogenic variants of the disease also shed light on the molecular pathogenesis
in typical sporadic PD.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is one of the most common neurodegen-
erative disorders, second in prevalence only to Alzheimer's disease,
and affects about 1 to 2% of individuals over the age of 60. It is
estimated that in the EU alone there are more than 500,000 affected
with PD, and the number is steadily increasing due to demographic
changes in Western countries.
It is assumed that PD is caused, in most cases, by an interplay of
genetic susceptibility factors and the “environment”, acting on the
background of an ageing brain. In fact, ageing is probably the single
most important “environmental” risk factor that eventually tips the
balance towards neurodegeneration and PD in a genetically suscep-
tible individual.
For over one and a half centuries after its initial description by
James Parkinson in 1817, the cause of the disease remained completely
obscure. It is only in the past 25 years that signiﬁcant advances have
beenmade in the understanding of PD pathogenesis andmost of them
were made possible by the identiﬁcation of genes for monogenic
forms of the disease, i.e. those with a clear “Mendelian”, autosomal-
dominant or autosomal-recessive, pattern of inheritance.
The role of those genes and loci causingMendelian forms of PD and
of their importance for the PD population as a whole will be the
subject of the present review (Table 1).
Although the notion that the etiology of PD has a signiﬁcant
genetic contribution had not entered the mainstream of medicale.
ll rights reserved.thinking until recent years, there have been occasional reports on
genetic clusters or even PD families already in the ﬁrst half of the
twentieth century. One of the earliest systematic genetic studies of PD
was carried out by Henry Mjönes in Sweden and published in 1949.
His results, which depended heavily on a single extended family,
which is now known to carry an α-synuclein multiplication [13],
indicated autosomal-dominant transmission with 60% penetrance
[14]. These conclusions, however, were long discounted because
oligosymptomatic relatives and those with an atypical clinical
presentation were counted as secondary cases without clear justiﬁca-
tion. Subsequent surveys of patient and twin studies largely failed to
conﬁrm evidence of familial aggregation and the hypothesis of a
genetic etiology was over-shadowed by interest in possible environ-
mental neurotoxins. This led Roger Duvoisin to conclude, in 1987, that
“the best available data do not support a role of heredity in the
etiology of PD” [15].
In the following years, however, a growing number of pedigrees
with clinically more or less typical, and in some cases histologically
conﬁrmed Lewy-body PD was reported, particularly one extended
family originating from Southern Italy, the “Contursi kindred” [16,17],
and three families described byWszolek et al., [18] which appeared to
fall completely within the spectrum of what had to be considered
clinically and pathologically “typical” PD. In addition, Fluorodopa
positron emission tomography (PET) studies in oligo- or asympto-
matic co-twins of probands with PD showed much higher con-
cordance rates than previously thought [19], so in 1992, Duvoisin
concluded that “these ﬁndings favour monogenic autosomal-
dominant inheritance and show reason to argue against a multi-
factorial etiology or heteroplasmy” [20].
Table 1
PD genes
Locus Inheritance Gene Comments Ref.
PARK1 AD α-Synuclein First PD gene identiﬁed.
Protein is a major
component of Lewy-body
[1]
PARK2 AR Parkin Most common form of
autosomal-recessive
juvenile parkinsonism
[2]
PARK3 AD SPR? Gene not known
with certainty
[3]
PARK4 AD α-Synuclein Duplications and triplications
of the SNCA gene
[4]
PARK5 AD UCH L1 Role uncertain [5]
PARK6 AR PINK1 Second most common
form of AR-JP
[6]
PARK7 AR DJ-1 Rare [7]
PARK8 AD LRRK2 Most common form of
dominant PD
[8,9]
PARK9 AR ATP13A2 Complex phenotype
with parkinsonism,
spasticity and dementia
[10]
PARK11 AD GIGYF2 ? Role of gene not yet certain [11]
PARK13 AD ? OMI/HtrA2 No cosegregation shown
to support pathogenicity
[12]
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somewhat simplistic, it was still of remarkable foresight. Since then,
genes and mutations for a growing number of Mendelian forms of PD
have been identiﬁed in rapid succession.
2. Autosomal-dominant forms of Mendelian PD
2.1. The PARK1 locus (SNCA, α-synuclein)
The ﬁrst “PD gene” was mapped in a large family of clearly
dominant inheritance, which was already mentioned above, the
“Contursi-kindred”, named after the village of origin of at least one
branch of this pedigree, in Southern Italy. By linkage mapping, the
gene was located to the long arm of chromosome 4 [21] and a
missense mutation (Ala53Thr) in the gene for α-synuclein (SNCA)
was found to segregate with the disease in all but one affected (this
one affected being a “phenocopy”, i.e. an individual with PD from an
apparently different cause) [1]. Interestingly, already in this ﬁrst
report, the mutation was also identiﬁed in two smaller families from
the Western region of Greece. Haplotype data suggested that the
mutations in all families originated from a common founder. The
mutation was later found in several other families throughout the
world, which all could be traced back to Mediterranean ancestry and
had the same set of DNA-marker alleles (haplotype) on their
mutation-carrying chromosomes, indicating that they all reﬂect a
single historical mutational event and originate from a common
founder [22,23]. Only very recently, a second, independent A53T
mutation was identiﬁed in a Korean Parkinson patient [24].
Only two additional different point mutations in the SNCA gene
have subsequently been identiﬁed in families with dominantly
inherited PD, A30P in a German kindred [25], and E46K in a family
from Spain [26]. SNCA point mutations have so far only been found in
large, multigenerational families, never in sporadic PD [27].
The phenotype of patients with SNCA A53T and E46K point
mutations is that of L-dopa-responsive parkinsonismwith a relatively
early age of onset, rapid progression and high prevalence of dementia,
psychiatric and autonomic disturbances, although for all of these
features the range was relatively wide, and the families included
individuals indistinguishable from typical late-onset sporadic PD as
well as those who would fulﬁl present criteria for dementia with
Lewy-bodies. In a formal comparison of patients with familial PD from
Greece with and without A53T mutation, only the earlier onset age(mean difference ∼12 years) and a lower rate of tremor at onset were
speciﬁc for A53T carriers [28]. The A30P mutation, on the other hand,
seems to lead to a later age of onset and a milder phenotype, although
this analysis is based on a very small number of patients [25].
A number of family members from these kindreds have come to
autopsy and they invariably showed cell loss of dopaminergic neurons
of the substantia nigra, and severe and widespread Lewy-pathology,
particularly in the form of Lewy-neurites, not only in the substantia
nigra and other brain-stem nuclei, but also in the limbic system, the
hippocampus and throughout the neocortex. Interestingly, many
inclusions were also stained with Tau-antibodies [29], while classical
Lewy-bodies were relatively rare.
Therefore, the clinical and pathological picture of dominant PD
with SNCA mutations clearly overlaps, but is not identical with typical
sporadic late-onset PD.
A direct link between α-synuclein and PD was strongly supported
by the recent discovery that not only point-mutations, but also
multiplications of the wild-type sequence of the α-synuclein gene
(duplications and triplications) cause parkinsonism with or without
dementia with α-synuclein inclusions [4,30] in some families. This
type of mutation, also called “genomic rearrangement”, has recently
been found to be numerically and mechanistically important in many
diseases, and has escaped detection by classic gene sequencing
methods. Its role in PD has ﬁrst been described in a family known as
the “Spellman–Muenter kindred”. Linkage mapping in this family had
originally placed the gene on the short arm of chromosome 4, (4p15),
hence the locus has been named PARK4. When subsequently it was
found that the causative mutation was actually the triplication of a
genomic region on 4q23 containing the SNCA-gene, the locus
designation was nevertheless upheld as a PARK-locus involving
genomic rearrangements affecting the SNCA-gene.
This ﬁnding was of major mechanistic importance because it
indicates that a mere increase in SNCA gene dosage, resulting in a
doubling of α-synuclein protein levels, which can also be measured
in the blood and in the brain in cases with triplications [31], appears
to be toxic to neurons. This link between α-synuclein expression
levels and disease was further supported by the observation that
patients with an SNCA-triplication generally have an early age of
onset (mean 35 in the original triplication family) and a high
prevalence of dementia, while patients described subsequently with
SNCA-duplications, corresponding to a 1.5-fold increase in α-
synuclein protein load, have a more typical late-onset PD-phenotype
[32]. This was conﬁrmed in a single noteworthy family, the kindred
described by Henry Mjönes in 1949 [14], in whom one branch was
found to segregate an SNCA-duplication, corresponding to a late-
onset phenotype, while in another branch the identical fragment of
about 600 kb, carrying only the SNCA gene (and one other gene,
MMRN1, which is not expressed in the nervous system), was found
triplicated in a patient with an early disease onset of 35 years. This
“dose-dependency” of the pathogenic effect clearly supports the
direct role of SNCA-expression levels as one possible mechanism
underlying Parkinson's disease. Due to the late onset, it is not
surprising that SNCA-duplications can occasionally be found also in
sporadic patients [33]. Although on a population level, dosage
changes of SNCA are probably more frequent than point mutations,
again overall they are a rare cause of dominant parkinsonism and are
very rare in the sporadic disease [34,35].
In accordance with the early onset and severe rapidly progressive
phenotype with the early development of dementia in the kindred
described by Mjönes, neuropathology showed severe changes not
only in the substantia nigra, but also in many other regions of the
brain. Therewas striking cortical pathology, with regions of spongiosis
and gliosis accompanied by scattered glial cells with α-synuclein-
immunoreactive inclusions somewhat similar to glial cytoplasmic
inclusions of multiple system atrophy. α-Synuclein-immunoreactive
round to pleomorphic inclusions were also found within neurons,
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described as cortical Lewy-bodies in dementia with Lewy-bodies
(DLB). This ﬁnding supports the assumption that Lewy-body diseases,
including PD and DLB can be seen as part of a spectrum reﬂecting the
same pathogenic process in variable levels of severity.
As SNCA-multiplications clearly indicate that an increase in
expression of the wild-type gene can be pathogenic, there has been
considerable interest in studies looking at polymorphisms in SNCA,
which might inﬂuence expression levels, as a potential risk factor in
the sporadic disease. Early studies looking at a complex polymorphic
dinucleotide repeat polymorphism (NACP-Rep1) located about 4 kb
upstream of the transcriptional start site of SNCA have initially
produced controversial results, but a meta-analysis summarizing data
of over 2500 individuals appeared to conﬁrm initial ﬁndings of an
association with sporadic PD [36].
In a more general approach, Müller et al. ﬁrst deﬁned the
haplotype structure of the entire SNCA-gene by analyzing more than
50 SNPs across the gene. They found a strong association of a
haplotype comprising exons 5 and 6 and the 3′-UTR of the SNCA gene
with PD, conferring a relative risk of about 1.4 in heterozygous carriers
of the risk haplotype and about 2 in homozygotes [37]. A weaker
signal was also found in the promotor region, conﬁrming earlier
results [38,39]. It is therefore likely that more than one region of the
SNCA gene is involved in the regulation of α-synuclein expression and
consequently modulates PD risk. The association with the 3′-
haplotype block with a similar relative risk has since been replicated
in numerous populations from Japan [40], the UK [41] and Germany
[42].
The mechanism, by which these variants inﬂuence the risk for
PD is still unclear. The NACP-Rep1-polymorphism has been best
studied in this regard. Speciﬁc binding of a nuclear protein, Poly
(ADP ribose) polymerase-1 (PARP-1) to the NACP-Rep1-sequence
was recently discovered [43] and allele-speciﬁc binding of this
protein may be responsible, at least in part, for altered expression
levels that have been found in white blood cells in vivo [44]. In
addition to differential binding of transcription factors to the
promotor or of enhancers or suppressors to intronic regions, it is
also possible that genetic variability in the 3′-UTR modiﬁes
translation by inﬂuencing RNA-stability, conformation or transport.
It could be hypothesized that this could lead to local areas of
increased α-synuclein concentration where oligomerization is
initiated, which is then propagated in a seeding-dependent fashion.
If further conﬁrmed, pharmacologic manipulation of α-synuclein
expression may be a possible therapeutic strategy to prevent PD in
susceptible individuals.
Although α-synuclein mutations are rare, their identiﬁcation was
of course extremely important, as it led to the discovery that the
encoded protein is the major ﬁbrillar component of the Lewy-body
[45], the proteinaceous inclusion which has, since Friedrich Lewy's
original description in 1917, been considered to be the pathologic
hallmark of PD in both familial and sporadic cases.
This and many other lines of evidence support a central role of α-
synuclein in the development of PD, and α-synuclein staining has
replaced staining for ubiquitin as the most sensitive tool in the
detection of Lewy-bodies. The currently favoured hypothesis states
that the amino acid changes in the α-synuclein protein associated
with PD may favour the β-pleated sheet conformation of the protein
over the natively unstructured form that is usually predominant. This
in turn is thought to lead to an increased tendency to form aggregates
[46]. However, the precise relationship between the formation of
aggregates and cell death is unknown. It has been hypothesized that a
failure of proteasomal degradation of α-synuclein and other proteins
may lead to an accumulation of toxic compounds, possibly consisting
of α-synuclein oligomers and protoﬁbrils [47], ultimately leading to
cell death [48]. Another possible mechanism could be a deﬁcient
chaperone-mediated lysosomal clearance of α-synuclein [49].Mechanistic aspects of α-synuclein pathogenicity are discussed in
more detail elsewhere in this volume.
α-Synuclein point mutations and also gene dosage mutations are
too rare to warrant mutational analysis on a routine basis except in
cases when the disease clearly segregates in a dominant fashion in a
large family. SNCA risk variants, on the other hand, are common in the
population, but confer only a slightly increased risk to develop the
disease (odds ratio of 1.5 to 2) and therefore are only of limited value
for individual risk prediction. They may however be useful at some
point to stratify populations, for example if preventive or disease-
modifying treatments become available that modify α-synuclein
expression levels.
2.2. PARK8: leucine-rich repeat kinase 2 (LRRK2)
Another major locus for an autosomal-dominant Mendelian form
of PD was ﬁrst mapped in a large Japanese family to the pericen-
tromeric region of chromosome 12 and named PARK8. Affected in this
family showed typical L-dopa responsive parkinsonism with onset in
their late ﬁfties [50]. Linkage to this locus was conﬁrmed and reﬁned
in two families of Caucasian background [51], and by a positional
cloning approach, different missense mutations in a large gene called
leucine-rich repeat kinase 2 (LRRK2) [8,9] were found to cosegregate
with the disease in these and several other families. The observation of
different missense changes in highly conserved codons linked to the
disease in a number of large families is strongly supportive of their
pathogenic role.
Soon it became clear that mutations in the LRRK2 gene are a much
more common cause of inherited parkinsonism than those in the
SNCA gene. In a number of studies across several different popula-
tions, between 5 to 15% of dominant families carried mutations in the
LRRK2 gene [52,53]. One particularly common mutation is a basepair
change, a G–NA transition at position 6055, better known as the
“G2019S-mutation”, which is responsible for familial PD in up to 7% of
cases in different Caucasian populations [54–56], but also in 1 to 2% of
sporadic patients [57]. Similar to the A53T SNCA mutation, haplotype
analysis suggested that the mutation can be traced back to probably a
few founder events [56,58] in different populations, indicating that
the mutation has been passed down for many centuries. Even higher
G2019S prevalence rates of up to 40% were found in genetically more
isolated populations, such as the Ashkenazi Jewish and the North
African Berber Arab populations, both in sporadic and familial cases
[59,60], again explained by a genetic founder effect. Particularly the
high prevalence in sporadic cases suggests a reduced penetrance of
this mutation [61], which must be taken into account when
counseling patients and families. Based on the type of study (family
ascertainment vs. population based) estimates of penetrance vary
between 35 and 85%, but are in any case of course highly age-
dependent. Another old, population-speciﬁc mutation is commonly
encountered in the Basque population in Northern Spain, involving
codon 1441 (R1441G) [62].
The most extensive study so far estimated the overall frequency of
LRRK2 mutations in the European population to about 1.5% in
sporadic and 4% in familial cases, with a geographic gradient
decreasing from the Mediterranean countries (Spain, Portugal, and
Italy) to the North.
A large collaborative clinicogenetic study collecting clinical data on
356 LRRK2 mutation carriers showed that the average age of onset
was 58 years, with a wide range from the mid-twenties (rarely!) to
over 90 years [63]. The clinical picture was that of typical asymmetric
levodopa responsive parkinsonism that was indistinguishable by any
single criterion from PD in nonmutation-carriers. As a group however,
the disease appears to be somewhat more benign in LRRK2 positive
patients, which is reﬂected in a longer duration to reach equivalent
Hoehn-and-Yahr stages, and a lower frequency of dementia and
psychiatric complications. Although the data are still limited it also
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80–100% in sporadic PD).
Due to its relatively high frequency, the G2019S mutation for the
ﬁrst time offers the possibility to look at gene–gene interactions.
Dächsel et al. identiﬁed three Spanish patients simultaneously
harboring heterozygous mutations in the LRRK2 and in the parkin
gene. In comparison to other Spanish patients with a single LRRK2
mutation, the three double-mutation patients did not present with an
earlier age-at-onset or a faster progression of disease [64]. Given the
questionable pathogenicity of heterozygous parkin mutations (see
below), this ﬁnding is not surprising.
The G2019S mutation also seems to be fully dominant, as
homozygous mutation carriers have been identiﬁed who also do not
differ from heterozygotes with respect to disease severity or age of
onset [54].
The LRRK2 gene is very large and spans a genomic region of 144 kb,
with 51 exons encoding 2527 amino acids. To date, more than 20
potential mutations have been identiﬁed so far. It must be remem-
bered, however, that only six of them can at this point be considered
proven to be pathogenic (R1441C, R1441G, R1441H, Y1699C, G2019S,
and I2020T), because of ﬁrm evidence of cosegregation in affected
families. This does not necessarily mean that other reported rare
variants, that often have been found in sporadic PD patients or small
families but not in several hundred controls, are not; but the
possibility remains that they may represent rare polymorphisms,
which is of course of major importance for genetic counseling.
Early-on the possibility was investigated whether common
polymorphisms in the LRRK2 gene may contribute to the risk of
developing sporadic PD, as was shown for the SNCA gene (see above).
Two extensive studies in European populations using tagging single
nucleotide polymorphisms (tSNPs) failed to detect any associated
variants or haplotypes [65,66], while a similar study in Chinese
patients detected an association signal [67], indicating possible
population speciﬁc effects. In fact, this assumption was clearly
conﬁrmed by the subsequent identiﬁcation of at least 2 relatively
common risk variants in the Asian (Chinese as well as Japanese)
population: the variant G2385R was found in approximately 6 to 9% of
Chinese patients with PD ([68–70], as compared to 2 to 4% in controls,
conferring a relative risk of about 2. Again, haplotype analyses
suggested an ancient mutationwith a common founder [71]). Another
risk variant R1628P of nearly similar strength was also identiﬁed in
Chinese patients [72,73], again representing a single ancient muta-
tional event. Remarkably, both variants together explain about 10% of
the risk for sporadic PD in this Asian population (population
attributable risk). These studies clearly demonstrate that some
mutations in the LRRK2 act as high penetrance Mendelian disease
genes, whereas others operate as risk alleles. Molecular studies will
have to show whether the mechanism of action in these instances is
the same, just of different strengths, or different. As in the case of
SNCA risk variants, determination of risk alleles will only have limited
clinical usefulness for individual risk prediction, as obviously other
factors are required to lead to the manifestation of the disease, at least
during a usual lifespan. Once the molecular mechanisms of the risk
modiﬁcation are deciphered, however, the path is open to stratify
patient cohorts for speciﬁc LRRK2 directed disease-modifying treat-
ments. If only the 10% disease risk attributable to these two variants
could be signiﬁcantly reduced, this would be a tangible success on the
population level.
Many aspects of LRRK2 associated PD remain to be elucidated,
some of which are dealt with in other contributions to this issue. For
example, the mechanism by which LRRK2 mutations cause neuronal
degeneration is still unknown. By sequence homology, LRRK2 can be
assigned to the group of recently identiﬁed ROCO-proteins [74] and
contains a protein kinase domain of the MAPKKK class, suggesting a
role in intracellular signaling pathways. Although the natural
substrate of LRRK2 is unknown, cell culture studies suggest that atleast some pathogenic mutations seem to be associated with an
increase, rather than a loss, of kinase activity [75–77], and that kinase
activity appears to be necessary for neurotoxicity in vitro [78], raising
the interesting possibility that kinase inhibition may be a potential
therapeutic strategy.
Another puzzling aspect of LRRK2 related PD is its pathology. Post
mortem changes in patients with LRRK2 mutations are consistent
with typical Lewy-body Parkinson's disease in most cases reported so
far [79], but also include diffuse Lewy-body disease, nigral degenera-
tion without distinctive histopathology and, rarely, even progressive
supranuclear palsy-like tau aggregation. All these pathologic ﬁndings
were reported in a single family with an R1441C mutation [8]. LRRK2
mutations may therefore be an upstream event in the cascade leading
to neurodegeneration with different pathologies. On the other hand,
mutation-speciﬁc effects are conceivable. The vast majority of patients
with a G2019S mutation, in whom pathology has been reported, seem
to conform to the typical α-synuclein Lewy-body type of PD [79],
while in the original Japanese family with an I2020T mutation, nigral
degeneration without prominent inclusions seems to be dominating
the pathologic picture [80].
Despite its still enigmatic role in pathogenesis, LRRK2 associated
PD is of particular interest since it is the ﬁrst example of a Mendelian
form of PD that is common enough to provide the opportunity to
study the development of the disease in a sizeable population.
Longitudinal studies in presymptomatic mutation carriers may reveal
pre-motor changes by clinical, biochemical or imaging methods,
indicating the very early phases of the neurodegenerative process. It is
in this population that studies exploring neuroprotective or pre-
ventive measures, be it speciﬁc for the LRRK2 associated pathways or
more general, are most promising to yield ﬁrst results.
3. Recessive forms of Mendelian PD
One of the interesting developments of recent years was the
recognition of the relatively high proportion of patients with a
monogenically inherited form of parkinsonism following autosomal-
recessive transmission. So far, three of the causative genes, parkin
PRKN (PARK2), PINK1 (PARK6) and DJ-1 (PARK7) have been cloned.
One other recessive gene (ATP13A2, PARK9) has been identiﬁed in
patients with early-onset parkinsonism, spasticity and dementia. It is
likely that several other loci exist. Currently, the genes for parkin PRKN
and PINK1 are numerically clearly the most important causes for
autosomal-recessive juvenile-onset parkinsonism (AR-JP).
4. Autosomal-recessive juvenile parkinsonism caused by
mutations in the parkin gene
Cases of parkinsonism with early disease-onset and recessive
inheritance (families with affected siblings, but usually no transmis-
sion from one generation to the next) were ﬁrst recognized and
described as a clinical entity in Japan [81]. Clinically, these patients
suffered from L-dopa-responsive parkinsonism with onset in the
second to fourth decade. Some of the patients showed diurnal
ﬂuctuations with symptoms becoming worse later in the day, similar
to patients with dopa-responsive dystonia (DRD), which is caused by
mutations in the gene for GTP-cyclohydrolase [82], one of the genes
involved in dopamine biosynthesis. In contrast to patients with DRD,
however, patients with recessive parkinsonism develop often early
and severe levodopa-induced motor-ﬂuctuations and dyskinesias. In
other respects, however, the disease seemed to progress slowly and
development of dementia was relatively rare. Dystonia at onset of the
disease was found to be a common feature. The disorder was called
autosomal-recessive juvenile parkinsonism (AR-JP).
The ﬁrst genetic locus for AR-JP was mapped by linkage analysis in
a set of 13 Japanese families to the long arm of chromosome 6 [83].
This region was analyzed as a candidate locus bearing the gene for
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eses of oxidative stress and mitochondrial dysfunction being involved
in the pathogenesis of PD. The locuswas later conﬁrmed and reﬁned in
different ethnic groups [84,85], excluding SOD2 from the reﬁned
region.
Positional cloning eventually identiﬁed several homozygous
deletions in consanguineous families with AR-JP in a large gene in
this region that was named parkin (PRKN) [2,86].
PRKN mutations turned out to be a common cause of parkinson-
ism with early onset, and novel mutations were reported in rapid
succession [87–89]. All types of mutations, including missense
mutations leading to amino acid exchanges, nonsense mutations
resulting in premature termination of translation and exonic
rearrangements (deletions, duplications and triplications) were
identiﬁed [90].
A number of studies have delineated the clinical spectrum
associated with parkin mutations. By and large, the clinical picture is
frequently indistinguishable from that of the sporadic disease, with
the notable exception of course of the earlier age-at-onset. The vast
majority of patientsmanifest the disease before the age of 40, very few
patients with disease-onset in their ﬁfties have been described [91].
For example, a large collection of European sib pairs collected by
the European Consortium on Genetic Susceptibility in PD (GSPD)
allowed the characterization of the clinical spectrum of parkin-
associated parkinsonism [89]. Mean age at onset was 32 years,
progression of the disease was slow but L-dopa associated ﬂuctuations
and dyskinesias occurred early and frequently. Brisk reﬂexes of the
lower limbs were present in 44%.
Comparing young-onset carriers and non-carriers of parkin
mutations, those with a mutation tended to have earlier and more
symmetrical onset, slower progression of the disease and greater
response to L-dopa despite lower doses. Lower limb dystonia at
disease-onset occurred in about a third of the patients, but this feature
did not appear to be speciﬁc for parkin-related disease, and was more
correlated with the age at onset than with genetic status [92].
Nevertheless, dystonia at disease-onset can be prominent enough to
render distinction from dopa-responsive dystonia difﬁcult [93].
In the initial European study by Lücking et al., there was no
discernable difference in the clinical phenotype between patients
with missense mutations, truncating point mutations or deletions,
suggesting that a complete loss of Parkin function is associated with
all of these mutations and with the full phenotype of early-onset
parkinsonism. More recent phenotype–genotype studies by the same
group in an extended sample however suggested that the type of
mutation may in fact inﬂuence the clinical phenotype to a certain
degree: patients with at least one missense mutation showed a faster
progression of the disease with a higher UPDRS (United Parkinson's
Disease Rating Scale) motor score than carriers of truncating
mutations. Missense mutations in functional domains of the parkin
gene resulted in earlier onset [92]. A very similar clinical picture was
described in Japanese patients, but age of onset was still lower
(average about 26 years) [94].
Although the majority of patients with parkin mutations in most
series conform to this relatively well deﬁned clinical picture, a
minority will present with unusual features, including cervical
dystonia, autonomic dysfunction and peripheral neuropathy, exer-
cise-induced dystonia [95], or camptocormia [96]. Further clinical
features that can be seen in parkin disease: focal dystonia; early
postural instability; severe and early freezing; festination or retro-
pulsion; concurrent autonomic failure; dramatic response to antic-
holinergics; early or atypical L-dopa-induced dyskinesias; exquisite
sensitivity to small doses of L-dopa; and recurrent psychosis, even
taking L-dopa alone [95]. Psychiatric and behavioural disorders prior
to the onset of parkinsonism have also been recognized in patients
with parkin mutations [94,95]. Exceptionally, patients with parkin
mutations may even present with a clinical picture of levodopaunresponsive parkinsonism complicated by cerebellar and pyramidal
tract dysfunction [97].
Functional neuroimaging in parkin-linked parkinsonism consis-
tently demonstrated a severely reduced uptake of dopamine tracer in
both hemispheres in the putamen and caudate nucleus [98], which
differs at least quantitatively from the initially unilateral reduction in
dopa uptake of sporadic PD patients [99]. In terms of the rostro-caudal
gradient of tracer-uptake in the putamen (the decrease being more
severe in the posterior portion), the pattern of uptake in YOPD
patients is similar to that of patients with idiopathic Parkinson's
disease and does not depend on the presence or absence of mutations
of the parkin gene [100].
Khan et al. have used [18F]dopa PET serially to study members of a
family with young-onset parkinsonism who are compound hetero-
zygous for mutations in the parkin gene, to assess disease progression.
The parkin patients showed a signiﬁcantly slower loss of putamen
[18F]dopa uptake compared with a group of idiopathic Parkinson's
disease (IPD) patients who had baseline putamen [18F]dopa uptake
and disease severity similar to the parkin group. One study also
provided evidence for an alteration of postsynaptic mechanisms,
indicated by a reduced binding of the D2-receptor ligand 11C-
raclopride [101]. This ﬁnding is remarkable, as it is usually associated
with an impaired response to dopaminergic medication, which is
clearly not typical of parkin-disease.
Numerically, parkin mutations are the major cause of early-onset
parkinsonism in cases with recessive inheritance. In a group of 73
sibling pairs with PD, at least one of them having an age at onset
before 45 years, 50% were due to parkin mutations [89]. The
prevalence of Parkin-associated parkinsonism in a population of
sporadic patients strongly depends on age at onset. Taking into
account a number of different studies, PRKN mutations probably
account for about 5 to 10% of early-onset cases (onset before 45 years)
without family history. Within this group, the proportion of mutation-
carriers increases signiﬁcantly with decreasing age at onset (82% in
those with an onset before age 20 years) [102]. A similar distribution
has been found in Japanese patients [103].
AR-JP caused by PRKN mutations is an autosomal-recessive
disorder with high penetrance. Homozygous or compound hetero-
zygous disease gene carriers will develop the disease with an age
dependent penetrance. Apparently dominant inheritance of parkin-
related disease may be found when multiple disease alleles are
segregating within a single family (which may occur particularly in
the context of consanguinity)[104].
The question whether (speciﬁc?) heterozygous parkin mutations
may cause or increase the susceptibility to late-onset typical PD is
still a matter of debate. It is well established that heterozygous
carriers of parkin mutations have reduced [18F]-Fluorodopa-uptake
by PET [101,105], even in the absence of clinical symptoms, which
has been interpreted as a “ﬁrst hit” by the genetic abnormality to the
dopaminergic system. Some larger multicase-pedigrees have been
ascertained on the basis of typical early-onset parkin-related cases of
parkinsonism in patients with two parkin mutations. Heterozygous
carriers of parkin mutations in these families are obviously common
and have been found to exhibit either minor signs of basal ganglia
dysfunction [106] or present with late-onset parkinsonism [91,107].
In at least two of these cases, typical Lewy-bodies have been
described at autopsy, suggesting that a hetero- or hemizygous parkin
mutation may be a risk factor for typical LB-positive PD. However,
PD is a common condition, and an occasional occurrence of PD due
to different causes in a single family is a well documented
possibility. Therefore, the causal relationship between heterozygous
parkin mutations and disease status is still not completely clear.
Studies screening late-onset PD cases and healthy, age-matched
controls for parkin mutations found similar frequencies of genetic
variants, on the order of about 3%, suggesting that heterozygous
parkin mutations generally do not confer a signiﬁcantly increased
592 T. Gasser / Biochimica et Biophysica Acta 1792 (2009) 587–596risk for late-onset PD [108,109]. On the other hand, “healthy”
controls in these studies have usually not been examined carefully
for minor signs of parkinsonism.
Even 10 years after the identiﬁcation of the parkin gene, there is
still relatively little information available on the neuropathology of
molecularly conﬁrmed cases of parkin-related AR-JP. Severe and
selective degeneration of dopaminergic neurons and gliosis in the
substantia nigra pars compacta, and, to a somewhat lesser degree, of
the locus coeruleus, has been described [110–112]. Lewy-bodies or
other α-synuclein-containing Lewy-pathology have not been
described in several studies, suggesting that the disease process in
parkin-related cases may differ in some important ways from that in
typical idiopathic PD. Lewy-bodies are thought to represent a
mechanism whereby cells sequester damaged and toxic proteins in
an inactive form. The ubiquitin–proteasome system (UPS) is involved
in the detoxiﬁcation of these proteins, so complete loss of Parkin,
which is an E3-ubiquitin ligase and therefore a component of the UPS,
may be sufﬁcient to prevent LB formation. On the other hand,
however, several cases have also been described with parkinsonism,
parkin mutations and positive Lewy-bodies at autopsy [107,113,114].
The signiﬁcance of this ﬁnding is still unclear but it may indicate that
some speciﬁc parkin mutations retain sufﬁcient activity to allow LB-
formation. This has been supported by experimental studies indicat-
ing that mutations in the RING-domain retain ubiquitin ligase activity
[107], and that certain point mutations may confer a toxic gain of
function, leading to Parkin protein aggregation and aggresome
formation [115].
To further address the possible role of Parkin in sporadic PD,
several association studies with coding and non-coding polymorph-
isms within the parkin gene have been performed. Overall, the results
of these studies are still inconclusive. Some positive results have been
reported [116–118] but not fully corroborated by other studies
[119–122]. The general feeling is that common variants in the parkin
gene are probably not of major relevance in sporadic late-onset PD.
5. Autosomal-recessive juvenile parkinsonism caused by
mutations in the PINK1-gene
In a large Italian family with autosomal-recessive early-onset
parkinsonism, Valente et al. (2001) identiﬁed a novel locus, PARK6, in
a 12.5-cM region of 1p36–p35. The large Sicilian family, which the
authors designated the Marsala kindred, had 4 deﬁnitely affected
members. The phenotype was characterized by early-onset (range 32
to 48 years) parkinsonism, with slow progression and sustained
response to levodopa. In this and two other consanguineous PARK6-
linked families, Valente et al. identiﬁed two different mutations in the
gene for PINK1 [6]. Cell culture studies indicated that PINK1 is
mitochondrially located and may exert a protective effect on the cell
that is abrogated by the mutations, resulting in increased suscept-
ibility to cellular stress.
A number of studies conﬁrmed the presence of PINK1mutations in
patients with early-onset PD [123–127]. Most mutations were
missense mutations in conserved regions, but also whole gene
deletions have been described [128].
In a review of 21 patients with PINK1-related parkinsonism
reported in the literature, Albanese et al. found that most patients (95
to 100%) had slow disease progression, good response to levodopa,
bradykinesia, and rigidity. Also common were levodopa-induced
dyskinesias, resting tremor, and asymmetry at onset, postural
instability (63%), on/off phenomenon (60%), and gait impairment
(55%). As in parkin disease, except of the earlier average age of onset,
no single feature can separate PINK1-disease from idiopathic PD
[129]. There are some indications that PINK1-mutated patients have a
higher prevalence of psychiatric disturbances, particularly anxiety
and depression, which is only relatively rarely observed in parkin
cases [130].Exceptionally, a compound heterozygous PINK1 mutation can be
found also in sporadic patients with a phenotype indistinguishable
from idiopathic Parkinson's disease (PD), with onset in the late
seventh decade, rapid progression and good response to levodopa that
waned with time, underlining the existing difﬁculties in discriminat-
ing between Mendelian parkinsonism and idiopathic PD [131].
The PINK1 protein has been located, at least in good part, at the
mitochondrial compartment, where it may act as a protein kinase
[123]. In Drosophila, a deletion of the PINK1 gene leads to a marked
mitochondrial phenotype. Interestingly, this phenotype can be largely
rescued by the overexpression of the parkin gene, suggesting that both
proteins act in a common pathway, which is related to mitochondrial
function and integrity [132].
No pathology has yet been reported in patients with PINK1
mutations.
6. Autosomal-recessive juvenile parkinsonism caused by
mutations in the DJ-1 gene
The third locus for AR-JP, PARK7, was mapped also to chromosome
1p36, in a Dutch family [133], and the gene was identiﬁed as the
oncogene DJ-1 [7]. Again, the phenotype closely resembles that found
in patients with parkin and PINK1 mutations, but this statement is
based on a rather small number of identiﬁed patients [134,135]. On the
other hand, one recessive family has been described with early-onset
parkinsonism, dementia and ALS, which carries two homozygous
mutations in the DJ-1 gene, suggesting that the clinical phenotype
associated with mutations in this gene, although rare, may be rather
wide [136]. The associated pathology is still unknown, as no autopsies
have been reported.
The function of the DJ-1 protein is not entirely clear. The favoured
hypothesis is that it acts as a sensor for oxidative stress, providing
neuroprotection in situations of increased demand [137].
7. Relevance of recessive PD-genes to the late-onset
sporadic disease
The question of the relevance of mutations in the recessive PD-
genes for the development of sporadic PD and the relationship of the
pathogenic pathways is still controversial. Differences in pathology of
AR-JP and sporadic PD may point to different pathogenic cascades,
but they may also be related to differences in age and disease
dynamics between these groups. Current evidence, also presented
elsewhere in this volume, suggests that the recessive PD-genes exert
a neuroprotective function against a variety of insults, with a
common theme emerging with relation to mitochondrial function
and integrity [138–140]. Whether enhancing this protective function
can be a future therapeutic or disease-modifying strategy in PD
remains to be elucidated. In any case, recessive forms of PD certainly
represent a valuable “model” to study the effects of the loss of
speciﬁcally deﬁned protective mechanisms on the survival of
dopaminergic neurons.
8. Other genes and loci
Several other loci have been mapped in families with PD and
apparently Mendelian inheritance, but either the genes have not yet
been identiﬁed, or their role is still somewhat controversial. A
dominant locus has been described on chromosome 2p13 (PARK3)
[3]. Clinical features relatively closely resemble those of sporadic
PD. So far, however, the gene has not been identiﬁed in these
families. Interestingly, several independent recent reports implicate
the PARK3-locus as a disease modifying locus inﬂuencing age at
onset in two sib pair cohorts with PD [141,142] and a European sib
pair study also identiﬁed a linkage peak in this region [143]. A
further study reﬁned this association to a region containing the
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study [145]. Sepiapterine reductase is involved in dopamine
synthesis. This ﬁnding may indicate that the SPR gene is modifying
the age of onset of PD, but the potentially causative variants have
not been identiﬁed.
A heterozygous missense mutation in the gene for ubiquitin
carboxy-terminal hydrolase L1 gene (UCHL1, PARK5), which is located
on chromosome 4p has been identiﬁed in an affected single family of
German ancestry [5]. To date, no other bona ﬁde pathogenic mutations
of this gene have been identiﬁed, and the segregation of the mutation
in the original family does not sufﬁciently support the contention of
UCHL1 being a dominant disease gene. Nevertheless, a common
polymorphism in the UCHL1 gene, the S18Y variant, has been
suggested to be associated with sporadic PD in several studies,
including a large meta-analysis [146]. Still, whether UCHL1 is really a
PD-gene is not clear yet.
Another locus has been mapped on chromosome 1 in an Icelandic
population(PARK10)[147],butthegenehasnotyetbeenidentiﬁedandit
isunclear,whether the locusplaysa role inotherpopulationsalso.
Finally, a locus on chromosome 2q has been mapped in a mixed
Caucasian population from the US [148], but the locus has not been
conﬁrmed in another cohort of European families [149]. Nevertheless,
recent report provided evidence for mutations in a gene in this region,
GIGYF2, or GBR10 interacting GYF protein-2, which encodes a
component of the insulin signaling pathway [11]. Four different
sequence changes have been identiﬁed in conserved regions of the
gene, mostly in relatively small families with PD. In some cases,
unaffected family members were identiﬁed to also carry themutation,
and none of the families were large enough to unequivocally
demonstrate cosegregation of mutation and disease. A recent study
failed to conﬁrm a strong association of mutations in the GIGYF2 gene
in two other populations with PD [150] so that their pathogenic role is
still uncertain.
Mutations in several other genes have been reported in PD patients
without linkage evidence from large families. Therefore, the genetic
proof of pathogenicity is lacking. Although functional studies in cell
culture support a possible pathogenic effect of these mutations, as is
the case for the mitochondrial protease OMI/HtrA2 [12]. In still other
cases, the possible role of a gene in PD is suggested by the clinical
observation of association, as found in the case of Gaucher's disease.
Relatives of patients with this well characterized recessive neurome-
tabolic disease, caused by mutations in the glucocerebrosidase gene
(GBA) have a conspicuously high prevalence of PD. Screening of PD
patients for GBA mutations then found a higher number of hetero-
zygous mutations carriers as compared to healthy controls [151]. This
has now been conﬁrmed in several other populations with very
similar odds ratios [152–154]. Mutations have been found in about 2
to 4% of Caucasian PD patients, and less than 1% of controls. However,
those variants are likely to act as risk factors rather than as high
penetrance Mendelian disease genes.
9. Conclusion
The identiﬁcation and characterization of Mendelian forms of PD
has sparked an extremely fruitful line of research, delineating
molecular pathways that are involved in dopaminergic cell dysfunc-
tion and death. It is becoming increasingly clear that those pathways
are not only relevant for these rare Mendelian variants of PD, but also
to the PD population as a whole.
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